ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / GMED
PODD (72) BAX (50) PEN (57) SOLV (44) ⌘ Pro Terminal →

Globus Medical Inc. (GMED) — RQD Stock Rating Cockpit

$78.05 -5.86% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $77.08

Globus Medical Inc. (GMED) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) →
ROARABLE C+ • HOLD / WATCH Cap $10.48B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GMED Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Globus Medical Inc. (NYSE: GMED) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $78.05 (-5.86% 1D, market cap $10.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, GMED ranks #83 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GMED compare to PODD and BAX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), GMED carries a Roarable C+ (69/100 RQD), trailing P/E of 20.7x, gross margin of 67.4%, and ROIC of 8.7%. By comparison, PODD (Insulet Corporation) holds a B grade (72/100 RQD, P/E 42.8x, ROIC 20.4%, cap $10.38B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GMED?
▼

Per GMED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001237831), Globus Medical Inc. generated $2.94B in revenue (+16.7% YoY), $537.9M in net income, and $588.8M in free cash flow against $5.30B in total assets and $328.3M in total debt. Key quantitative strengths: Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $77.08 (-1.24%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 20% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B
Cash (16)Whales (9)SEC (18)Macro (11)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$106 Bull$82 Base$64 Bear
📬 FREE GMED RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GMED)Realized 20D OHLCV Swing Band: ±6%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY GMED SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 10.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 20% FCF Margin ($588.8M FCF) & 67.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$76.31+3.1% Next Q
Q2 (-2Q)
64
Grade C+$78.68+3.3% Next Q
Q3 (-1Q)
66
Grade B-$81.26-4% Next Q
Current
69
Grade C+$78.05+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GMED Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, GMED faces multiple-compression risk if 20.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 64.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($77.41) or 200D SMA ($83.31) invalidates the momentum regime and cuts Target Base ($81.91) toward Bear Floor ($63.89).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GMED• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GMED Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
4830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
10.74>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE43% OF RANGE
L: $60$78.05H: $101
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (67% profit margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on GMED

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

8.7% ROIC with 67.4% gross margin and 5.29% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 10.74 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (58)

24/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like GMED
  • ✓Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GMED Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GMED // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.85%📐 HORIZONTAL RANGE
2026-11-03O $82.91H $82.91L $78.05C $78.05VOL 1.68M
RES: $82.99SUP: $72.17SMA50: $77.41SMA200: $83.31
$93.38$87.73$82.09$76.44$70.79RES $82.99SUP $72.17$78.052026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GMED Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GMED Butterfly Map → + Track GMED →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
14.3%/yr Implied 5Y Growth

vs. +16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GMED today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GMED. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GMED today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GMED)

Health Care Rank #83 of 1016 ⚔️ PODD vs GMED Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GMED vs. PODD, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Globus Medical Inc. (GMED) ranks #83 by composite RQD confidence (69/100, grade C+) and #104 by equity capitalization ($10.48B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with GMED at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GMED ACTIVE
Globus Medical Inc.
C+ 69/100 20.7x 67.4% 8.7% -5.86% $10.48B Benchmark Subject
PODD
Insulet Corporation
B 72/100 42.8x 71.6% 20.4% -1.85% $10.38B /podd-vs-gmed →
BAX
Baxter International Inc.
D 50/100 — 30.1% -2.4% -2.13% $11.90B /bax-vs-gmed →
PEN
Penumbra Inc.
D+ 57/100 71.4x 67.1% 10.6% -0.94% $12.57B /pen-vs-gmed →
SOLV
Solventum Corporation
D 44/100 9.1x 53.5% 18.7% -2.67% $13.84B /solv-vs-gmed →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001237831

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Globus Medical Inc. (GMED) reported GAAP revenue of $2.94B (+16.7% vs. FY2024 revenue of $2.52B , and +87.4% cumulative change since FY2023) , GAAP net income of $537.9M, operating cash flow of $753.4M, and free cash flow of $588.8M (+45.3% YoY). On the balance sheet, GMED closed FY2025 with $5.30B in total assets against $328.3M in total debt (Altman Z-Score: 10.74, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.94B $537.9M $753.4M $588.8M $5.30B $328.3M
FY2024 (FY) 2024-12-31 $2.52B $103.0M $520.6M $405.2M $5.25B $483.5M
FY2023 (FY) 2023-12-31 $1.57B $122.9M $243.5M $172.9M $6.12B $1.43B

3. GMED Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GMED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Globus Medical Inc. (NYSE: GMED) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $78.05 (-5.86% 1D, market cap $10.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, GMED ranks #83 in composite RQD confidence.

How does GMED compare to PODD and BAX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), GMED carries a Roarable C+ (69/100 RQD), trailing P/E of 20.7x, gross margin of 67.4%, and ROIC of 8.7%. By comparison, PODD (Insulet Corporation) holds a B grade (72/100 RQD, P/E 42.8x, ROIC 20.4%, cap $10.38B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GMED?

Per GMED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001237831), Globus Medical Inc. generated $2.94B in revenue (+16.7% YoY), $537.9M in net income, and $588.8M in free cash flow against $5.30B in total assets and $328.3M in total debt. Key quantitative strengths: Strong cash generator (67% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GMED trading relative to its 50-day, 200-day, and 52-week technical levels?

GMED last traded at $78.05 (-5.86% on volume of 1,677,113 shares), positioning the stock +0.83% above its 50-day simple moving average ($77.41) and -6.31% below its 200-day simple moving average ($83.31). Across its 52-week range of $60.26 to $101.40, GMED sits at the 43.2% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($73.37 to $82.73).

GMED Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell GMED stock right now?

Globus Medical Inc. (GMED) currently earns a Roarable Rating of C+ (Hold — HOLD) with 69/100 RQD Confidence. Solid 67% profit margin (9% return on capital), mixed timing at 21x P/E—hold if owned, no rush to chase.

What is GMED's 12-month price target and RQD AI Jury consensus?

GMED's 12-month base price target is $81.91 (range $63.89 to $106.47), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: GMED RQD Cockpit GMED 12M Forecast GMED Earnings & Move GMED Dividends & DRIP GMED Insiders & 13F GMED Whale Options GMED Profit Sankey GMED News & Why
ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GMED — Globus Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, GMED scores 72 out of 100 with a letter grade of B and the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine at 16/20 (ROIC 8.7%; FCF yield 5.29%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 15/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.07; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 10.74; Piotroski F 9/9; Debt/Equity 0.07). The strongest pillar is the forensic balance sheet, which indicates low financial-distress risk per the metrics provided. The weakest is macro regime fit, where the beta of 1.07 implies the stock has moved slightly more than the market in the source's framing, so broader market weakness could carry through to the shares. Upside drivers in the source data are the cash-generation metrics and the balance-sheet strength. Valuation tradeoffs are visible in the multiples: a trailing P/E of 20.7 compared with a forward P/E of 17.4 and EV/EBITDA of 17.6. Whale-flow and macro pillars are the lower-scoring components and merit closer monitoring. This is an analytical summary of the source data, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
82.91$11.13B20.717.417.64.010%1.07$59.51 - $101.48.7%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$2938.9M$479.8M$537.9MN/A$588.8M$526.2M$328.3M
FY 2024$2519.4M$166.0M$103.0MN/A$405.2M$784.4M$483.5M
FY 2023$1568.5M$133.1M$122.9MN/A$172.9MN/A$1432.6M

Revenue rose across the three reported periods, from $1568.5M to $2938.9M, and net income in FY 2025 ($537.9M) exceeded operating income ($479.8M). Per the market data, the net margin is 18.3% and ROIC is 8.7%. The source provides a forensic balance-sheet score of 18/20, with an Altman Z-Score of 10.74, a Piotroski F-Score of 9/9, and a Debt/Equity ratio of 0.07. Reported debt fell from $1432.6M in FY 2023 to $328.3M in FY 2025.

Recent Catalysts & News Wire Analysis

  • Risk Watch (RED): "Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Split On Outlook" (Yahoo Finance). The headline signals a modest downward fair-value revision and analyst disagreement.
  • Catalyst (GREEN): "Globus Medical (NYSE:GMED): A Quality Investing Case Built on Durable Growth" (ChartMill).
  • Market Wire (YELLOW): "Globus Medical (GMED) Stock Looks Undervalued Even After A 77% Run" (Yahoo Finance). The headline references a 77% run; the period is not specified in source data.
  • Market Wire (YELLOW): "Globus Medical (NYSE:GMED) Stock Forecast & Analyst Predictions" (Simply Wall St).
  • Market Wire (YELLOW): "Globus Medical Q2 2026 Earnings Call Transcript" (Benzinga). The transcript content is not included in source data.
  • Catalyst (GREEN): "Globus Medical (NYSE:GMED): A Balanced Affordable Growth Case" (ChartMill).

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What products, customers, and revenue mix drive the reported revenue growth from $1568.5M to $2938.9M?
  • What is the basis for the "modest fair value cut" and the analyst split referenced in the risk-watch headline?
  • What are the reported EPS figures, since the financials show EPS as N/A for all periods?
  • What caused the sharp swing in net income between FY 2024 ($103.0M) and FY 2025 ($537.9M)?
  • What is the time frame of the "77% run" referenced in the Yahoo Finance headline, and what the cash balance was in FY 2023?

GMED Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Globus Medical Inc. (GMED) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GMED Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GMED Bull vs. Bear Conversation Board — What's Your Call at $78.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GMED 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GMED:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $97.83 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GMED (B • RQD 72/100) a Buy at $82.91?

Welcome to the GMED (Globus Medical Inc.) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy — Good Risk/Reward) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $63.84 (-23.0%)
Spot @ $82.91

Pump the brakes on GMED — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GMED, but look at what you are paying: 20.7x trailing P/E with 67.4% gross margins. Unless Globus Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $96.18 (+16.0%)
Spot @ $82.91

GMED cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GMED, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $82.91 (52-wk range $59.51 - $101.40), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%